AXSM as reported
Axsome Therapeutics, Inc. reported $777M of revenue over the trailing twelve months, +57% on the year before. 10 reported series are charted on this page, each one as filed.
$777M
Revenue, trailing twelve months · to Q2 2026 · +57% against the twelve months before
- Net Income
- −$192M
Net Income · −22% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$72M
Free Cash Flow · −41% year on year · trailing twelve months to Q2 2026
- Op Margin
- −24%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $777M | +57% | Q2 2026 |
| Net Income | −$192M | −22% | Q2 2026 |
| EPS | −$3.74 | −26% | Q2 2026 |
| Gross Margin | 93% | n/a | Q2 2026 |
| Op Margin | −24% | n/a | Q2 2026 |
| Net Margin | −25% | n/a | Q2 2026 |
| ROE | −273% | n/a | Q2 2026 |
| ROA | −28% | n/a | Q2 2026 |
| ROIC | 266% | n/a | Q2 2026 |
| Free Cash Flow | −$72M | −41% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Axsome Therapeutics, Inc. (AXSM) - Revenue & ProfitRevenue & ProfitAxsome Therapeutics, Inc. (AXSM)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com